Joint Development And License Agreement Sample Contracts

Share Cite Term
Link

Embed (HTML)
AzurRx BioPharma, Inc. – Also Been Provided to the Securities and Exchange Commission. Joint Development and License Agreement (July 13th, 2016)
AzurRx BioPharma, Inc. – Also Been Provided to the Securities and Exchange Commission. Joint Development and License Agreement (June 16th, 2016)
AzurRx BioPharma, Inc. – Also Been Provided to the Securities and Exchange Commission. Joint Development and License Agreement (October 16th, 2015)
AzurRx BioPharma, Inc. – CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH "****" OR OTHERWISE CLEARLY INDICATED. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND EXCHANGE COMMISSION. JOINT DEVELOPMENT AND LICENSE AGREEMENT Between Laboratoires Mayoly Spindler SAS and Proteabio Europe SAS (September 8th, 2015)

Notwithstanding the foregoing, in the event LMS licenses, sub-licenses, or otherwise authorizes the use of the Patents and any LMS IP by a Third Party, LMS shall ensure that such Third-Party license, sub-license or other authorization does not adversely impact or otherwise restrict Protea's rights under this Agreement.

NantKwest, Inc. – Joint Development and License Agreement (July 27th, 2015)

This Joint Development and License Agreement (this Agreement) is made and entered into as of the 18th day of December, 2014 (the Effective Date), by and between CONKWEST INCORPORATED, a Delaware corporation with offices at 2533 South Coast Highway 101, Suite 210, Cardiff-By-The-Sea, CA 92007-2133 (CONKWEST), and SORRENTO THERAPEUTICS, INC., a Delaware corporation with offices at 6042 Cornerstone Ct. W., San Diego, Ca 92121 (SRNE). CONKWEST and SRNE are sometimes referred to herein individually as a Party and together as the Parties.

NantKwest, Inc. – Joint Development and License Agreement (June 19th, 2015)

This Joint Development and License Agreement (this Agreement) is made and entered into as of the 18th day of December, 2014 (the Effective Date), by and between CONKWEST INCORPORATED, a Delaware corporation with offices at 2533 South Coast Highway 101, Suite 210, Cardiff-By-The-Sea, CA 92007-2133 (CONKWEST), and SORRENTO THERAPEUTICS, INC., a Delaware corporation with offices at 6042 Cornerstone Ct. W., San Diego, Ca 92121 (SRNE). CONKWEST and SRNE are sometimes referred to herein individually as a Party and together as the Parties.

AMEDICA Corp – Joint Development and License Agreement (January 29th, 2014)

This Joint Development Agreement (the Agreement) entered into as of the 8th day of February, 2010 (the Effective Date) is by and between Amedica Corporation, a Delaware corporation with a principal place of business at 1885 West 2100 South, Salt Lake, City, Utah 84119 (Amedica) and Orthopaedic Synergy, Inc., a Delaware corporation with a principal place of business at 50 OConnell Way #10, East Taunton, MA 02718 (OSI). Amedica and OSI are each referred to herein as a Party and collectively as Parties.

AMEDICA Corp – Joint Development and License Agreement (November 15th, 2013)

This Joint Development Agreement (the Agreement) entered into as of the 8th day of February, 2010 (the Effective Date) is by and between Amedica Corporation, a Delaware corporation with a principal place of business at 1885 West 2100 South, Salt Lake, City, Utah 84119 (Amedica) and Orthopaedic Synergy, Inc., a Delaware corporation with a principal place of business at 50 OConnell Way #10, East Taunton, MA 02718 (OSI). Amedica and OSI are each referred to herein as a Party and collectively as Parties.

Second Amendment to Joint Development and License Agreement (August 4th, 2011)

For the avoidance of doubt, each of the foregoing milestone payments is a separate payment and shall be paid only once by Defiante. Consequently, the maximum amount that Defiante is obligated to pay to Dyax under this Section 7.2 (c) is [*****].

Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Asterisks Denote Such Omission. FIRST AMENDMENT TO JOINT DEVELOPMENT AND LICENSE AGREEMENT (March 2nd, 2011)

This FIRST AMENDMENT (the "First Amendment"), dated as of December 21, 2010 (the "Amendment Date"), is entered into by and between Dyax Corp., with principal offices at 300 Technology Square, Cambridge, Massachusetts 02139, U.S.A. ("Dyax"), and Defiante Farmaceutica S.A., with registered offices at Rua da Alfandega, n. 78, 3deg andar, 9000-059, Funchal, Madeira, Portugal ("Defiante"). This First Amendment amends that certain Joint Development and License Agreement (the "Original Agreement"), dated effective as of June 18, 2010 (the "Effective Date") by and between Dyax and Defiante. All capitalized terms not otherwise defined in this First Amendment shall be as defined in the Original Agreement.

Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Asterisks Denote Such Omission. JOINT DEVELOPMENT AND LICENSE AGREEMENT BY AND BETWEEN DYAX CORP. AND DEFIANTE FARMACEUTICA S.A., DATED AS OF JUNE 18, 2010 (August 2nd, 2010)
Third Extension Agreement to Joint Development and License Agreement (July 19th, 2010)

THIS THIRD EXTENSION AGREEMENT TO JOINT DEVELOPMENT AND LICENSE AGREEMENT (this Third Extension) is entered into as of July 14, 2010, by and among BP Biofuels North America LLC, a Delaware limited liability company (BP), Verenium Biofuels Corporation, a Delaware corporation (Verenium), and Galaxy Biofuels LLC, a Delaware limited liability company (Galaxy), each of which is referred to herein individually as a Party, and collectively as the Parties.

Second Extension Agreement to Joint Development and License Agreement (April 1st, 2010)

This SECOND EXTENSION AGREEMENT TO JOINT DEVELOPMENT AND LICENSE AGREEMENT (the Second Extension) is entered into as of March 31, 2010, by and among BP Biofuels North America LLC, a Delaware limited liability company (BP), Verenium Biofuels Corporation, a Delaware corporation (Verenium), and Galaxy Biofuels LLC, a Delaware limited liability company (Galaxy), each of which is referred to herein individually as a Party, and collectively as the Parties.

Extension Agreement to Joint Development and License Agreement (March 1st, 2010)

This EXTENSION AGREEMENT TO JOINT DEVELOPMENT AND LICENSE AGREEMENT (the Extension) is entered into as of February 26, 2010, by and among BP Biofuels North America LLC, a Delaware limited liability company (BP), Verenium Biofuels Corporation, a Delaware corporation (Verenium), and Galaxy Biofuels LLC, a Delaware limited liability company (Galaxy), each of which is referred to herein individually as a Party, and collectively as the Parties.

Amendment No. 1 to Joint Development and License Agreement (February 1st, 2010)

This AMENDMENT NO. 1 TO JOINT DEVELOPMENT AND LICENSE AGREEMENT (the Amendment) is entered into as of January 31, 2010, by and among BP Biofuels North America LLC, a Delaware limited liability company (BP), Verenium Biofuels Corporation, a Delaware corporation (Verenium), and Galaxy Biofuels LLC, a Delaware limited liability company (Galaxy), each of which is referred to herein individually as a Party, and collectively as the Parties.

Palomar Medical Technologies, Inc. – Fifth Amendment to the September 7, 2004 Joint Development and License Agreement Between Palomar Medical Technologies, Inc. And Johnson & Johnson Consumer Companies, Inc. (The Agreement) (August 5th, 2009)

Whereas, pursuant to the Agreement, the parties are engaged in a collaboration to develop, clinically test and potentially commercialize home-use, light-based devices for (i) reducing or reshaping body fat including cellulite; (ii) reducing appearance of skin aging; and (iii) reducing or preventing acne; and

Anadys Pharmaceutical – Material Terms of the Joint Development and License Agreement Between LG Life Sciences and Anadys Pharmaceuticals, Inc. (December 20th, 2007)

On April 18, 2004, we entered into a global joint development and license agreement with LGLS (the LGLS Agreement) for the clinical development and commercialization of ANA380 for the treatment of chronic HBV infection. Under the terms of the LGLS Agreement, we were sharing the costs for the global clinical development of ANA380 with LGLS and were granted a license for the future commercialization of ANA380 in the territories of North America, Europe, Japan and the rest of the world other than China, Korea, India and countries in Southeast Asia. In connection with the execution of the LGLS agreement, we paid a licensing fee of $4 million during May 2004 to LGLS. In addition, if the LGLS Agreement had continued and certain development and commercialization objectives had been achieved, we would have had the potential obligation to make additional milestone payments totaling up to $25.5 million. Also under the LGLS Agreement, we would have owed royalties to LGLS on any future product sal